Ipilimumab-Associated lymphocytic colitis: A case report

Translational Gastroenterology and Hepatology

Volumn 5, Issue 1, 2016, Pages 44-46

  Romain, Paul E St ^a   Salama, April K S ^a   Lynn Ferguson, N ^a   Burbridge, Rebecca A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Ipilimumab; Lymphocytic colitis; Melanoma metastatic; Microscopic

Indexed keywords

BUDESONIDE; IPILIMUMAB;

ABDOMINAL CRAMP; ABNORMAL FECES; ADULT; APOPTOSIS; ARTICLE; CASE REPORT; COLON BIOPSY; COLONOSCOPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPHOCYTIC COLITIS; LYMPHOCYTOSIS; METASTATIC MELANOMA; MIDDLE AGED; POLYMERASE CHAIN REACTION; TENESMUS; TUMOR VOLUME; WATERY STOOL;

EID: 84994748520     PISSN: 2224476X     EISSN: 22244778     Source Type: Journal    
DOI: 10.3978/j.issn.2224-4778.2015.10.11     Document Type: Article

References (7)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
2. Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010;10:11.
3. Andrews S, Holden R. Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res 2012;4:299-307.
4. Oble DA, Mino-Kenudson M, Goldsmith J, et al. Alpha-CTLA-4 mAb-Associated panenteritis: A histologic and immunohistochemical analysis. Am J Surg Pathol 2008;32:1130-7.
5. García-Varona A, Odze RD, Makrauer F. Lymphocytic colitis secondary to ipilimumab treatment. Inflamm Bowel Dis 2013;19:E15-6.
6. Johnston RL, Lutzky J, Chodhry A, et al. Cytotoxic T-lymphocyte-Associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009;54:2538-40.
7. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-8.